These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12478881)

  • 1. Double-blind antiglucocorticoid treatment in schizophrenia and schizoaffective disorder: a pilot study.
    Marco EJ; Wolkowitz OM; Vinogradov S; Poole JH; Lichtmacher J; Reus VI
    World J Biol Psychiatry; 2002 Jul; 3(3):156-61. PubMed ID: 12478881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiglucocorticoid treatment of depression: double-blind ketoconazole.
    Wolkowitz OM; Reus VI; Chan T; Manfredi F; Raum W; Johnson R; Canick J
    Biol Psychiatry; 1999 Apr; 45(8):1070-4. PubMed ID: 10386195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiglucocorticoid and related treatments for psychosis.
    Garner B; Phillips LJ; Bendall S; Hetrick SE
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD006995. PubMed ID: 26725721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
    Janicak PG; Glick ID; Marder SR; Crandall DT; McQuade RD; Marcus RN; Eudicone JM; Assunção-Talbott S
    J Clin Psychiatry; 2009 Jan; 70(1):25-35. PubMed ID: 19192472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of depression with antiglucocorticoid drugs.
    Wolkowitz OM; Reus VI
    Psychosom Med; 1999; 61(5):698-711. PubMed ID: 10511017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin B6 as add-on treatment in chronic schizophrenic and schizoaffective patients: a double-blind, placebo-controlled study.
    Lerner V; Miodownik C; Kaptsan A; Cohen H; Loewenthal U; Kotler M
    J Clin Psychiatry; 2002 Jan; 63(1):54-8. PubMed ID: 11838627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of schizoaffective disorder and schizophrenia with mood symptoms.
    Levinson DF; Umapathy C; Musthaq M
    Am J Psychiatry; 1999 Aug; 156(8):1138-48. PubMed ID: 10450252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.
    Perkins DO; Gu H; Weiden PJ; McEvoy JP; Hamer RM; Lieberman JA;
    J Clin Psychiatry; 2008 Jan; 69(1):106-13. PubMed ID: 18312044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot randomized, controlled trial of pramipexole to augment antipsychotic treatment.
    Kelleher JP; Centorrino F; Huxley NA; Bates JA; Drake JK; Egli S; Baldessarini RJ
    Eur Neuropsychopharmacol; 2012 Jun; 22(6):415-8. PubMed ID: 22153972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder.
    Fu DJ; Turkoz I; Simonson RB; Walling DP; Schooler NR; Lindenmayer JP; Canuso CM; Alphs L
    J Clin Psychiatry; 2015 Mar; 76(3):253-62. PubMed ID: 25562685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial.
    Zisook S; Kasckow JW; Golshan S; Fellows I; Solorzano E; Lehman D; Mohamed S; Jeste DV
    J Clin Psychiatry; 2009 Apr; 70(4):562-71. PubMed ID: 19192468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spotlight on ziprasidone in schizophrenia and schizoaffective disorder.
    Gunasekara NS; Spencer CM; Keating GM
    CNS Drugs; 2002; 16(9):645-52. PubMed ID: 12153335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
    Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
    J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of glycine on auditory mismatch negativity in schizophrenia.
    Greenwood LM; Leung S; Michie PT; Green A; Nathan PJ; Fitzgerald P; Johnston P; Solowij N; Kulkarni J; Croft RJ
    Schizophr Res; 2018 Jan; 191():61-69. PubMed ID: 28602646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of brain-derived neurotrophic factor and cortisol to sulfate of dehydroepiandrosterone molar ratio associated with clinical response to L-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder patients.
    Miodownik C; Maayan R; Ratner Y; Lerner V; Pintov L; Mar M; Weizman A; Ritsner MS
    Clin Neuropharmacol; 2011; 34(4):155-60. PubMed ID: 21617527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
    Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD).
    Vieta E; Herraiz M; Fernández A; Gastó C; Benabarre A; Colom F; Martínez-Arán A; Reinares M
    J Clin Psychiatry; 2001 Aug; 62(8):623-30. PubMed ID: 11561935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.